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1. Introduction 
Acetylcholine is believed to play a major role in 
nervous transmission in the central nervous system 
of insects [l] . It has been reported that flies do not 
contain a nicotinic receptor similar to that of verte- 
brates, but that their cholinergic receptor is of a mixed 
nicotinic and muscarinic nature [2-61 and does not 
bind the powerful nicotinic antagonist cu-bungarotoxin 
[5,7] . I report here that flies do contain a nicotinic 
receptor that binds abungarotoxin specifically. The 
demonstration that the fruit fly, Drosophila melano- 
gaster, contains such a receptor, could permit one to 
study the genetic control of the receptor and the 
effects of mutations on its expression and activity. 
2. Materials and methods 
Most of the experiments were performed on heads 
of Drosophila melanogaster, C-S strain. Flies were 
cultured under standard conditions [8]. Heads were 
separated from bodies by freezing and shaking, and 
homogenized (400 heads/ml) in 0.32 M sucrose, in a 
glass-glass dual homogenizer followed by a glass- 
Teflon homogenizer. Routinely the supernatant of 
500 X g centrifugation for 10 min was used. House 
flies, Musca domestica, (Biological Institute, Ness- 
Ziona, Israel) were treated as above, except that 
40 heads/ml were taken for homogenization. 
a-Bungarotoxin (a-Bfx) was purified from crude 
Bungarus multicintus venom (Miami Serpentarium 
Miami, USA) [9] and was iodinated according to 
Vogel et al. [lo] . Binding of 1251-labelled ol-Btx was 
assayed by two methods: 
(i) Aliquots of fly homogenate were incubated in 
North-Holland Publishing Company - Amsterdam 
0.12 M NaCl, 2 mg/ml BSA, 0.05 M Tris-Cl, pH 7.4 
(= Buffer l), in total vol. 0.2 ml. Reaction was carried 
out at 25°C and terminated by diluting with 2 ml 
buffer 1 followed immediately by vacuum filtration 
through a Millipore EGWP filter as described by Vogel 
and Nirenberg [ 1 l] . The filter was then washed 
3-times with 2 ml portions of Buffer 1 and counted. 
This method determines the amount of labelled toxin 
bound to membrane fragments. 
(ii) Aliquots were incubated as above in Buffer 1 
containing 0.1% Triton X-100, and reaction was 
terminated by precipitating the receptor-toxin 
complex in 35% saturated ammonium sulfate, as 
described by Aharonov et al. [ 121. The precipitates 
were washed 3-times with 2 ml portions of 35% 
ammonium sulfate on a glass-fiber filter (GF/C, 
Tamar, Israel) and the filter counted. This method 
determines the amount of labelled toxin bound both 
to particulate and soluble receptor. The two assay 
methods were initially used to estimate soluble and 
particulate a-Btx-binding activity in fly homogenates, 
since the bulk of the cholinergic receptor in such 
preparations had previously been reported to be in 
the supernatant of 100 000 X g centrifugation [2]. 
However, since almost all e-Btx-binding activity was 
found to be particulate (see below), either method 
could be used, and both yielded similar results. 
3. Results and discussion 
Over the concentration-ranges used binding observ- 
ed with given concentration of labelled toxin was 
linearly proportional to the amount of head homo- 
genate present. Specific binding of toxin, defined as 
total binding minus the binding occurring in the 
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Fig.1. The level of ‘ss-labelled oBtx-binding to Drosophila 
head homogenate after incubation for 1 h at various toxin 
concentrations. (A) Total binding in the presence and in the 
absence of 10e4 M nicotine. (B) Specific binding, calculated 
from A. Saturation corresponds to 0.9 pmol toxin-bound/ 
1 mg protein. 
presence of 0.1 mM nicotine, was saturable (fig. 1). 
After incubation for 1 h, maximum specific binding 
was obtained with toxin concentrations higher than 
15 nM. Maximal specific-binding corresponds to 
0.9 kO.4 pmol toxin bound/l mg head protein. Con- 
centration of toxin-binding sites in isolated bodies 
was found to be 0.1 pmol/mg. 
Subcellular fractionation studies indicated that 
about 90% of the binding-sites sediment after centrifuga- 
tion at 20 000 X g for 20 min, i.e., are located in a 
‘crude mitochondrial’ fraction. Boiling at 100°C for 
3 min abolished > 98% binding. 
The time-dependence of binding is described in 
fig.2. Under the conditions employed, binding reached 
equilibrium in about 30 min. Assuming a simple 
bimolecular reaction between toxin and receptor, 
one can calculate the on-rate-constant for the forma- 
tion of toxin-receptor complex to be K1 = 7 X lo-’ 
M-r s-r 
Specificity of toxin binding and pharmacological 
properties were studied by testing the effect of various 
concentrations of cholinergic ligands on binding. 
Conditions were chosen so that binding in the absence 
of added ligand was within the initial linear-portion 
of the rate-curve [ 131. Concentrations of various cho- 
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Fig.2. The time-dependence of ‘a51-labelled a-Btx-binding 
to Drosophila head homogenate. Incubation medium contain- 
ed 15 nM toxin and 120 pg head protein. 
linergic agonists and antagonists that inhibited “‘I- 
labelled a-Btx-binding by 50% (1se) are given in table 
It can be seen that out of those tested nicotine is the 
most powerful ligand. DLMuscarine had no effect at 
the concentrations tested. Dexetimide, a muscarinic 
antagonist reported to have a high affinity for fly 
cholinergic-receptor [6], was almost 3-orders of mag- 
Table 1 
Effect of various cholinergic ligands on “‘1-1abelled 
o-Btx-binding to Drosophila head homogenate 
1. 
Ligand I 50 
or-Btx 
Nicotine 
D-Tubocurarine 
Acetylcholinea 
Atropine 
Carbamylcholine 
Pilocarpine 
Dexetimide 
Decamethonium 
DL-Muscarineb 
5 X lo-“’ M 
8 X lo-’ M 
2X 1O-6 M 
2X 1O-5 M 
5 X lo-’ M 
9 X lo-’ M 
8X 1O-5 M 
5 X 1O-4 M 
9 X 1O-4 M 
> 10-a M 
aDetermined in the presence of lo-’ M diethylfluorophos- 
phate, which completely inhibits acetylcholinesterase but has 
no effect on ‘asI-labelled or-Btx-binding 
bDL-Muscarine (Sigma) had no effect up to a concentration of 
1 mM - Higher concentrations were not tested 
Aliquots containing 100-150 pg head protein were pre- 
incubated for 25 min with the appropriate concentration of 
ligand. Reaction was started by addition of ‘asI-labelled 
ol-Btx (15 nM) and was carried out for 2 min at 25°C. I,, was 
determined from plots of relative reaction rate versus ligand 
concentration. Dexetimide was a generous gift of Janssen 
Pharmaceutics, Beerse, Belgium. 
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nitude less potent than nicotine in protecting against 
1251-labelled’or-Btx-binding. 
Similar experiments were carried out on heads of 
the house fly, Musca domestica, previously employed 
by various authors to study insect cholinergic-receptor. 
Again specific-binding of a-Btx was found to be 
linearly proportional to the amount of tissue present. 
Ise-Values were found to be: nicotine 3 X 10m6 M, 
D-tubocurarine 4 X 10e6 M, atropine 4 X low5 M, 
Dexetimide 4 X 10m4 M. Binding-site concentration 
for heads was found to be 0.8 pmol/mg protein. 
The above data clearly indicate that flies do con- 
tain a nicotinic receptor that specifically binds a-Btx. 
The reaction kinetics and main pharmacological 
characteristics are essentially similar to those obtained 
with rat-brain [IS] , chick-embryo sympathetic neurons 
[ 161 and Aplysia ganglia [ 171. Decamethonium, which 
is a powerful inhibitor of a-Btx-binding in vertebrate 
muscle, is much less effective in all the above systems, 
as well as in flies. 
The concentration of cu-Btx-binding sites reported 
above is one to two orders of magnitude below that 
reported for nicotinic-muscarinic binding sites in 
Musca head [2,6], but is in the range reported for 
a-Btx-binding sites in electric organ of the electric eel 
[ 181 and an order of magnitude higher than in mamms- 
lian brain [ 151. The fly cholinergic-receptor ligand- 
binding measured in previous studies may be due to 
several classes of receptors [3,4] , where by its specifi- 
city a-Btx-binding presumably reveals only the nico- 
tinic-receptor. It is therefore plausible to assume that 
flies contain more than one type of cholinergic- 
receptor and that the nicotinic-receptor comprises 
only a small fraction of the total. Such situation, as 
well as differences in methods employed in prepara- 
tion of homogenates, may account for the fact that 
cw-Btx-binding sites in insects were not previously 
detected [ 5,7] . 
The demonstration of a-Btx-binding sites in 
Drosophila is of interest not only because of its 
phylogenetic significance but also because the system 
is readily amenable to genetic analysis. Thus, the 
effect of genetic lesion, receptor- and other choliner- 
gic macromolecule, -coding genes on the development 
and behavior of the organism, and on the structural 
properties of the molecules themselves, could be 
studied. In this respect it is of interest to note that the 
structural gene for acetylcholinesterase has already 
been identified [ 191 and that effect of the mutated- 
gene on fly acetylcholinesterase molecules and 
behavior are under investigation [ 141. 
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